Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
F2G22B + DL001Z
- Development stage
- Approved
- Lead developer
- GSK
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
F2G22B + DL001Z is an experimental mRNA-based multivalent seasonal influenza vaccine candidate developed by GSK. It is part of a Phase 2a randomized, observer-blind, dose-finding study (GSK4382276A) designed to evaluate the safety and immunogenicity of various mRNA vaccine formulations in healthy younger and older adults. The vaccine utilizes messenger RNA technology to instruct host cells to produce viral antigens, typically hemagglutinin, which then stimulate the immune system to generate neutralizing antibodies and cellular immune responses against multiple strains of the influenza virus. This specific formulation is one of several candidates being tested to optimize the valency and dosage for seasonal protection.
- Other names
- GSK mRNA multivalent influenza vaccine
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on F2G22B + DL001Z.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on F2G22B + DL001Z.